Radiat Oncol J.  2019 Mar;37(1):37-42. 10.3857/roj.2018.00542.

Survival outcomes after adjuvant radiotherapy for aggressive fibromatosis depend on time frame and nuclear β-catenin

• Kim JS
• Kim HJ
• Lee MY
• Moon KC
• Song SG
• Kim HS
• Han I
• Kim IH

• KMID: 2447550
• DOI: http://doi.org/10.3857/roj.2018.00542

Abstract

PURPOSE
To identify prognostic factors influencing progression-free survival (PFS) of aggressive fibromatosis (AF) after postoperative radiotherapy (PORT) and assess correlations between immunohistochemistry (IHC) features of β-catenin/smooth muscle actin (SMA) and PFS.
MATERIALS AND METHODS
Records of 37 patients with AF treated by PORT from 1984 to 2015 were retrospectively reviewed. Fifteen patients underwent wide excision for AF and 22 patients received debulking operation. The median total dose of PORT was 59.4 Gy. IHC staining results of β-catenin and SMA were available for 11 and 12 patients, respectively.
RESULTS
The median follow-up duration was 105.9 months. Five-year PFS rate was 70.9%. Tumor size or margin status was not related to PFS in univariate analysis (p = 0.197 and p = 0.716, respectively). Multivariate analysis showed that increased interval from surgery to PORT (>5.7 weeks) was a marginal risk factor for PFS (p = 0.054). Administration of PORT at the initial diagnosis resulted in significantly improved PFS compared to deferring PORT after recurrence (p = 0.045). Patient with both risk factors of deferring PORT after recurrence and interval from surgery to PORT >5.7 weeks had significantly lower 5-year PFS than patients without risk factor (34.1% vs. 100.0%; p = 0.012). Nuclear β-catenin intensity tended to inversely correlate with 5-year PFS, although it did not reach statistical significance (62.5% at low vs. 100.0% at high; p = 0.260). SMA intensity was not related to PFS (p = 0.700).
CONCLUSION
PORT should be performed immediately after surgery irrespective of margin status or tumor size especially in recurrent case. Nuclear β-catenin staining intensity of IHC might correlate with local recurrence.

Keyword

Aggressive fibromatosis; Adjuvant radiotherapy; Immunohistochemistry; Beta catenin; Progression-free survival

MeSH Terms

Actins
beta Catenin
Diagnosis
Disease-Free Survival
Fibromatosis, Aggressive*
Follow-Up Studies
Humans
Immunohistochemistry
Multivariate Analysis
Radiotherapy
Radiotherapy, Adjuvant*
Recurrence
Retrospective Studies
Risk Factors
Actins
beta Catenin